ID   MIP-101
AC   CVCL_H689
SY   MIP 101; MIP101
DR   cancercelllines; CVCL_H689
DR   ColonAtlas; MIP101
DR   Cosmic; 1374639
DR   GEO; GSM587038
DR   GEO; GSM1448116
DR   IARC_TP53; 4562
DR   Wikidata; Q54905751
RX   PubMed=2228514;
RX   PubMed=3442732;
RX   PubMed=7651727;
RX   PubMed=7757961;
RX   PubMed=10949995;
RX   PubMed=15902309;
RX   PubMed=20835245;
RX   PubMed=23671654;
RX   PubMed=25926053;
RX   PubMed=25960936;
CC   Group: Space-flown cell line (cellonaut).
CC   Doubling time: 22 hours (PubMed=3442732); 15.7 hours (PubMed=7757961).
CC   HLA typing: A*24:02,02:01; B*35:08,35:08; C*07:01,04:01 (PubMed=25960936).
CC   Microsatellite instability: Instable (MSI) (PubMed=23671654; PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (PubMed=7651727).
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Anecdotal: Have been flown in space on shuttle flights STS-70 and STS-85 to study growth in microgravity (PubMed=10949995).
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
ST   Source(s): PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,11
ST   D16S539: 12,13
ST   D21S11: 29,32.2
ST   D5S818: 13
ST   D7S820: 10,11.3
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 18,19
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 05-10-23; Version: 16
//
RX   PubMed=2228514;
RA   Wagner H.E., Thomas P., Wolf B.C., Zamcheck N., Jessup J.M.,
RA   Steele G.D. Jr.;
RT   "Characterization of the tumorigenic and metastatic potential of a
RT   poorly differentiated human colon cancer cell line.";
RL   Invasion Metastasis 10:253-266(1990).
//
RX   PubMed=3442732; DOI=10.3109/07357908709020314;
RA   Niles R.M., Wilhelm S.A., Steele G.D. Jr., Burke B., Christensen T.,
RA   Dexter D.L., O'Brien M.J., Thomas P., Zamcheck N.;
RT   "Isolation and characterization of an undifferentiated human colon
RT   carcinoma cell line (MIP-101).";
RL   Cancer Invest. 5:545-552(1987).
//
RX   PubMed=7651727;
RA   Kastrinakis W.V., Ramchurren N., Rieger K.M., Hess D.T., Loda M.,
RA   Steele G., Summerhayes I.C.;
RT   "Increased incidence of p53 mutations is associated with hepatic
RT   metastasis in colorectal neoplastic progression.";
RL   Oncogene 11:647-652(1995).
//
RX   PubMed=7757961; DOI=10.1016/0304-3835(95)03764-n;
RA   Thomas P., Gangopadhyay A., Steele G.D. Jr., Andrews C., Nakazato H.,
RA   Oikawa S., Jessup J.M.;
RT   "The effect of transfection of the CEA gene on the metastatic behavior
RT   of the human colorectal cancer cell line MIP-101.";
RL   Cancer Lett. 92:59-66(1995).
//
RX   PubMed=10949995; DOI=10.1290/1071-2690(2000)036<0367:MCRAAI>2.0.CO;2;
RA   Jessup J.M., Frantz M., Sonmez-Alpan E., Locker J.D., Skena K.,
RA   Waller H., Battle P., Nachman A., Weber M.E., Thomas D.A.,
RA   Curbeam R.L. Jr., Baker T.L., Goodwin T.J.;
RT   "Microgravity culture reduces apoptosis and increases the
RT   differentiation of a human colorectal carcinoma cell line.";
RL   In Vitro Cell. Dev. Biol. Anim. 36:367-373(2000).
//
RX   PubMed=15902309; DOI=10.1172/JCI23002;
RA   Tai I.T., Dai M., Owen D.A., Chen L.B.;
RT   "Genome-wide expression analysis of therapy-resistant tumors reveals
RT   SPARC as a novel target for cancer therapy.";
RL   J. Clin. Invest. 115:1492-1502(2005).
//
RX   PubMed=20835245; DOI=10.1038/nmeth.1503;
RA   Griffith M., Griffith O.L., Mwenifumbo J., Goya R., Morrissy A.S.,
RA   Morin R.D., Corbett R., Tang M.J., Hou Y.-C., Pugh T.J., Robertson G.,
RA   Chittaranjan S., Ally A., Asano J.K., Chan S.Y., Li H.-Y.I.,
RA   McDonald H., Teague K., Zhao Y.-J., Zeng T., Delaney A., Hirst M.,
RA   Morin G.B., Jones S.J.M., Tai I.T., Marra M.A.;
RT   "Alternative expression analysis by RNA sequencing.";
RL   Nat. Methods 7:843-847(2010).
//
RX   PubMed=23671654; DOI=10.1371/journal.pone.0063056;
RA   Lu Y.-H., Soong T.D., Elemento O.;
RT   "A novel approach for characterizing microsatellite instability in
RT   cancer cells.";
RL   PLoS ONE 8:E63056-E63056(2013).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//